Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan:  (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2)

Emma C. Hulshof; Maarten J. Deenen; Marga Nijenhuis; Bianca Soree; Nienke J. de Boer-Veger; Anne Marie Buunk; Elisa J.F. Houwink; Arne Risselada; Gerard A.P.J.M. Rongen; Ron H.N. van Schaik; Daan J. Touw; Jan van der Weide; Roos van Westrhenen; Vera H.M. Deneer; Henk Jan Guchelaar; Jesse J. Swen

doi:10.1038/s41431-023-01315-x

Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan: (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2)

Emma C. Hulshof, Maarten J. Deenen, Marga Nijenhuis^*, Bianca Soree, Nienke J. de Boer-Veger, Anne Marie Buunk, Elisa J.F. Houwink, Arne Risselada, Gerard A.P.J.M. Rongen, Ron H.N. van Schaik, Daan J. Touw, Jan van der Weide, Roos van Westrhenen, Vera H.M. Deneer, Henk Jan Guchelaar, Jesse J. Swen

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Abstract

Correction to: European Journal of Human Genetics, published online 28 November 2022 Supplementary Table 3 contained two incorrectly predicted phenotypes based on the described genetic variant combinations (rs number variants). Supplementary Table 3 has been simplified and updated accordingly. (Table presented.) Genotype to predicted phenotype translation to be programmed into laboratory information system. Genotype rs number variants Nucleotide at position Predicted phenotype UGT1A1: WILDTYPE/WILDTYPE UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G -:- *1/*1 (TA6/TA6) UGT1A1:*28/*37/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G TA:TA *28/*28 (TA7/TA7) UGT1A1:WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G -:TA *1/*28 (TA6/TA7) UGT1A1:*27/*27 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 A:A G:G -:- PM otherwise UGT1A1:WILDTYPE/*27 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:G -:- IM otherwise UGT1A1:WILDTYPE/*27_WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:G -:TA PM otherwise UGT1A1:*6/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C A:A -:- PM otherwise UGT1A1:WILDTYPE/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:A -:- IM otherwise UGT1A1:WILDTYPE/*6_WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:A -:TA PM otherwise UGT1A1:WILDTYPE/*27_WILDTYPE/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:A -:- PM otherwise This table includes UGT1A1 alleles with a minor allele frequency ≥ 1% in either the White, African or Asian population. According to the allele definition table of PharmGKB, there is no allele including two of the polymorphisms (, accessed on 16 December 2022). This suggests that alleles including two or more of these polymorphisms are either very rare or non-existent. For this reason, genotypes with 3 or 4 polymorphisms were not included in the translation table. In addition, in compound heterozygotes, both polymorphisms were considered to be on different alleles.

Original language	English
Pages (from-to)	1088-1089
Number of pages	2
Journal	European Journal of Human Genetics
Volume	31
Issue number	9
DOIs	https://doi.org/10.1038/s41431-023-01315-x
Publication status	Published - Sept 2023

Access to Document

10.1038/s41431-023-01315-x

1 (Systematic) Review article

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan
Hulshof, E. C., Deenen, M. J., Nijenhuis, M., Soree, B., de Boer-Veger, N. J., Buunk, A.-M., Houwink, E. J. F., Risselada, A., Rongen, G. A. P. J. M., van Schaik, R. H. N., Touw, D. J., van der Weide, J., van Westrhenen, R., Deneer, V. H. M., Guchelaar, H.-J. & Swen, J. J., Sept 2023, In: European Journal of Human Genetics. 31, 9, p. 982-987 6 p.
Research output: Contribution to journal › (Systematic) Review article › peer-review

Cite this

Hulshof, E. C., Deenen, M. J., Nijenhuis, M., Soree, B., de Boer-Veger, N. J., Buunk, A. M., Houwink, E. J. F., Risselada, A., Rongen, G. A. P. J. M., van Schaik, R. H. N., Touw, D. J., van der Weide, J., van Westrhenen, R., Deneer, V. H. M., Guchelaar, H. J., & Swen, J. J. (2023). Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan: (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2). European Journal of Human Genetics, 31(9), 1088-1089. https://doi.org/10.1038/s41431-023-01315-x

@article{d63d95f90819445e812d4b1dbdfb1a8a,

title = "Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan: (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2)",

abstract = "Correction to: European Journal of Human Genetics, published online 28 November 2022 Supplementary Table 3 contained two incorrectly predicted phenotypes based on the described genetic variant combinations (rs number variants). Supplementary Table 3 has been simplified and updated accordingly. (Table presented.) Genotype to predicted phenotype translation to be programmed into laboratory information system. Genotype rs number variants Nucleotide at position Predicted phenotype UGT1A1: WILDTYPE/WILDTYPE UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G -:- *1/*1 (TA6/TA6) UGT1A1:*28/*37/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G TA:TA *28/*28 (TA7/TA7) UGT1A1:WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G -:TA *1/*28 (TA6/TA7) UGT1A1:*27/*27 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 A:A G:G -:- PM otherwise UGT1A1:WILDTYPE/*27 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:G -:- IM otherwise UGT1A1:WILDTYPE/*27_WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:G -:TA PM otherwise UGT1A1:*6/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C A:A -:- PM otherwise UGT1A1:WILDTYPE/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:A -:- IM otherwise UGT1A1:WILDTYPE/*6_WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:A -:TA PM otherwise UGT1A1:WILDTYPE/*27_WILDTYPE/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:A -:- PM otherwise This table includes UGT1A1 alleles with a minor allele frequency ≥ 1% in either the White, African or Asian population. According to the allele definition table of PharmGKB, there is no allele including two of the polymorphisms (, accessed on 16 December 2022). This suggests that alleles including two or more of these polymorphisms are either very rare or non-existent. For this reason, genotypes with 3 or 4 polymorphisms were not included in the translation table. In addition, in compound heterozygotes, both polymorphisms were considered to be on different alleles.",

author = "Hulshof, {Emma C.} and Deenen, {Maarten J.} and Marga Nijenhuis and Bianca Soree and {de Boer-Veger}, {Nienke J.} and Buunk, {Anne Marie} and Houwink, {Elisa J.F.} and Arne Risselada and Rongen, {Gerard A.P.J.M.} and {van Schaik}, {Ron H.N.} and Touw, {Daan J.} and {van der Weide}, Jan and {van Westrhenen}, Roos and Deneer, {Vera H.M.} and Guchelaar, {Henk Jan} and Swen, {Jesse J.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to European Society of Human Genetics 2023.",

year = "2023",

month = sep,

doi = "10.1038/s41431-023-01315-x",

language = "English",

volume = "31",

pages = "1088--1089",

journal = "European Journal of Human Genetics",

issn = "1018-4813",

publisher = "Nature Publishing Group",

number = "9",

}

Hulshof, EC, Deenen, MJ, Nijenhuis, M, Soree, B, de Boer-Veger, NJ, Buunk, AM, Houwink, EJF, Risselada, A, Rongen, GAPJM, van Schaik, RHN, Touw, DJ, van der Weide, J, van Westrhenen, R, Deneer, VHM, Guchelaar, HJ & Swen, JJ 2023, 'Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan: (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2)', European Journal of Human Genetics, vol. 31, no. 9, pp. 1088-1089. https://doi.org/10.1038/s41431-023-01315-x

Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan: (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2). / Hulshof, Emma C.; Deenen, Maarten J.; Nijenhuis, Marga et al.
In: European Journal of Human Genetics, Vol. 31, No. 9, 09.2023, p. 1088-1089.

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

TY - JOUR

T1 - Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

T2 - (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2)

AU - Hulshof, Emma C.

AU - Deenen, Maarten J.

AU - Nijenhuis, Marga

AU - Soree, Bianca

AU - de Boer-Veger, Nienke J.

AU - Buunk, Anne Marie

AU - Houwink, Elisa J.F.

AU - Risselada, Arne

AU - Rongen, Gerard A.P.J.M.

AU - van Schaik, Ron H.N.

AU - Touw, Daan J.

AU - van der Weide, Jan

AU - van Westrhenen, Roos

AU - Deneer, Vera H.M.

AU - Guchelaar, Henk Jan

AU - Swen, Jesse J.

PY - 2023/9

Y1 - 2023/9

N2 - Correction to: European Journal of Human Genetics, published online 28 November 2022 Supplementary Table 3 contained two incorrectly predicted phenotypes based on the described genetic variant combinations (rs number variants). Supplementary Table 3 has been simplified and updated accordingly. (Table presented.) Genotype to predicted phenotype translation to be programmed into laboratory information system. Genotype rs number variants Nucleotide at position Predicted phenotype UGT1A1: WILDTYPE/WILDTYPE UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G -:- *1/*1 (TA6/TA6) UGT1A1:*28/*37/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G TA:TA *28/*28 (TA7/TA7) UGT1A1:WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G -:TA *1/*28 (TA6/TA7) UGT1A1:*27/*27 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 A:A G:G -:- PM otherwise UGT1A1:WILDTYPE/*27 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:G -:- IM otherwise UGT1A1:WILDTYPE/*27_WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:G -:TA PM otherwise UGT1A1:*6/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C A:A -:- PM otherwise UGT1A1:WILDTYPE/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:A -:- IM otherwise UGT1A1:WILDTYPE/*6_WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:A -:TA PM otherwise UGT1A1:WILDTYPE/*27_WILDTYPE/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:A -:- PM otherwise This table includes UGT1A1 alleles with a minor allele frequency ≥ 1% in either the White, African or Asian population. According to the allele definition table of PharmGKB, there is no allele including two of the polymorphisms (, accessed on 16 December 2022). This suggests that alleles including two or more of these polymorphisms are either very rare or non-existent. For this reason, genotypes with 3 or 4 polymorphisms were not included in the translation table. In addition, in compound heterozygotes, both polymorphisms were considered to be on different alleles.

AB - Correction to: European Journal of Human Genetics, published online 28 November 2022 Supplementary Table 3 contained two incorrectly predicted phenotypes based on the described genetic variant combinations (rs number variants). Supplementary Table 3 has been simplified and updated accordingly. (Table presented.) Genotype to predicted phenotype translation to be programmed into laboratory information system. Genotype rs number variants Nucleotide at position Predicted phenotype UGT1A1: WILDTYPE/WILDTYPE UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G -:- *1/*1 (TA6/TA6) UGT1A1:*28/*37/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G TA:TA *28/*28 (TA7/TA7) UGT1A1:WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:G -:TA *1/*28 (TA6/TA7) UGT1A1:*27/*27 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 A:A G:G -:- PM otherwise UGT1A1:WILDTYPE/*27 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:G -:- IM otherwise UGT1A1:WILDTYPE/*27_WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:G -:TA PM otherwise UGT1A1:*6/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C A:A -:- PM otherwise UGT1A1:WILDTYPE/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:A -:- IM otherwise UGT1A1:WILDTYPE/*6_WILDTYPE/*28/*37 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:C G:A -:TA PM otherwise UGT1A1:WILDTYPE/*27_WILDTYPE/*6 UGT1A1_rs35350960 UGT1A1_rs4148323 UGT1A1_rs8175347 C:A G:A -:- PM otherwise This table includes UGT1A1 alleles with a minor allele frequency ≥ 1% in either the White, African or Asian population. According to the allele definition table of PharmGKB, there is no allele including two of the polymorphisms (, accessed on 16 December 2022). This suggests that alleles including two or more of these polymorphisms are either very rare or non-existent. For this reason, genotypes with 3 or 4 polymorphisms were not included in the translation table. In addition, in compound heterozygotes, both polymorphisms were considered to be on different alleles.

U2 - 10.1038/s41431-023-01315-x

DO - 10.1038/s41431-023-01315-x

M3 - Erratum / corrigendum / retractions

SN - 1018-4813

VL - 31

SP - 1088

EP - 1089

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

IS - 9

ER -

Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM et al. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan: (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2). European Journal of Human Genetics. 2023 Sept;31(9):1088-1089. doi: 10.1038/s41431-023-01315-x

Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan: (European Journal of Human Genetics, (2022), 10.1038/s41431-022-01243-2)

Abstract

Access to Document

Fingerprint

Research output

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan

Cite this